ENDECE Featured in MedPage Today

On November 17, 2016, ENDECE was featured in an article by MedPage Today, titled SfN: Estradiol Analog May Lead to New MS Therapy. The article reports on the early data that suggests NDC-1308 may have remyelinating properties.
An investigational estrogen-like compound induced oligodendrocyte differentiation in vitro, and upregulated oligodendrogenesis genes, making it a potential candidate for a remyelinating therapy in multiple sclerosis (MS), researchers reported here.
Among several compounds that were investigated, NDC-1308 was most potent at inducing oligodendrocyte progenitor cell (OPC) differentiation in vitro, according to Steven Nye, PhD, and James Yarger, PhD, of Endece, the Mequon, Wis.-based company that is developing the drug.

Click Here To Read The Whole Article

Submit a Comment

Your email address will not be published. Required fields are marked *